Details of the Drug

General Information of Drug (ID: DMK0O7U)

Drug Name

Flutamide

Synonyms

Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1], [2]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

276.21

Topological Polar Surface Area (xlogp)

3.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is rapidly and completely absorbed [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: 90% of drug becomes completely available to its intended biological destination(s) [5]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 6 hours [6]
Metabolism: The drug is metabolized via plasma [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 38.79 micromolar/kg/day [7]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0095 mg/mL [4]

Chemical Identifiers

Formula: C11H11F3N2O3
IUPAC Name: 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
Canonical SMILES: CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F
InChI: InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
InChIKey: MKXKFYHWDHIYRV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3397
ChEBI ID: CHEBI:5132
CAS Number: 13311-84-7
DrugBank ID: DB00499
TTD ID: D0Y0SW
VARIDT ID: DR00846
INTEDE ID: DR0733
ACDINA ID: D00288

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Antagonist	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[11]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[10]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[12]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[10]
Cytochrome P450 1B1 (CYP1B1)	DE9QHP6	CP1B1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Prostate cancer

ICD Disease Classification

2C82.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Androgen receptor (AR)	DTT	AR	2.13E-01	-0.07	-0.11
Multidrug resistance-associated protein 1 (ABCC1)	DTP	MRP1	1.51E-01	-3.44E-01	-4.04E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	4.39E-01	-4.78E-02	-2.19E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	1.88E-01	-2.98E-02	-1.92E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	1.00E-03	1.34E-01	1.10E+00
Cytochrome P450 1B1 (CYP1B1)	DME	CYP1B1	2.23E-02	5.29E-01	4.59E-01
Cytochrome P450 1A1 (CYP1A1)	DME	CYP1A1	2.71E-02	-2.19E-01	-1.44E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	7.93E-02	-8.20E-02	-8.93E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Flutamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Flutamide and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[83]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Flutamide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[84]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Midostaurin.	Acute myeloid leukaemia [2A60]	[85]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Idarubicin.	Acute myeloid leukaemia [2A60]	[85]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Daunorubicin.	Acute myeloid leukaemia [2A60]	[85]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Oliceridine.	Acute pain [MG31]	[85]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Flutamide and Metronidazole.	Amoebiasis [1A36]	[83]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Flutamide and Ivabradine.	Angina pectoris [BA40]	[85]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Flutamide and Bepridil.	Angina pectoris [BA40]	[86]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Flutamide and Dronedarone.	Angina pectoris [BA40]	[86]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Flutamide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[87]
Hydroxyzine	DMF8Y74	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[85]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Cilostazol.	Arterial occlusive disease [BD40]	[85]
Voriconazole	DMAOL2S	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Voriconazole.	Aspergillosis [1F20]	[85]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Posaconazole.	Aspergillosis [1F20]	[85]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Flutamide and Levalbuterol.	Asthma [CA23]	[88]
Terbutaline	DMD4381	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Terbutaline.	Asthma [CA23]	[89]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Pirbuterol.	Asthma [CA23]	[89]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Salbutamol.	Asthma [CA23]	[88]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Flutamide and Formoterol.	Asthma [CA23]	[89]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[85]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[85]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Flutamide caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[90]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[85]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[85]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[85]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Flutamide and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[86]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Flutamide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[91]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[85]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[85]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[85]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[85]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Telithromycin.	Bacterial infection [1A00-1C4Z]	[85]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Retigabine.	Behcet disease [4A62]	[85]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Flutamide and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[92]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Loperamide.	Bowel habit change [ME05]	[93]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Eribulin.	Breast cancer [2C60-2C6Y]	[85]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Tamoxifen.	Breast cancer [2C60-2C6Y]	[85]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Flutamide and Toremifene.	Breast cancer [2C60-2C6Y]	[86]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Bosutinib.	Breast cancer [2C60-2C6Y]	[85]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[85]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[89]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Flutamide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[88]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[89]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Flutamide and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[89]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Flutamide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[89]
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of Flutamide and Anisindione.	Coagulation defect [3B10]	[94]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Oxaliplatin.	Colorectal cancer [2B91]	[85]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Flutamide and Isoproterenol.	Conduction disorder [BC63]	[88]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Halothane.	Corneal disease [9A76-9A78]	[85]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Propofol.	Corneal disease [9A76-9A78]	[95]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Sevoflurane.	Corneal disease [9A76-9A78]	[85]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Probucol.	Coronary atherosclerosis [BA80]	[85]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Clofazimine.	Crohn disease [DD70]	[85]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Flutamide and Mifepristone.	Cushing syndrome [5A70]	[86]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Flutamide and Pasireotide.	Cushing syndrome [5A70]	[86]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Osilodrostat.	Cushing syndrome [5A70]	[85]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Sertraline.	Depression [6A70-6A7Z]	[85]
Trimipramine	DM1SC8M	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Trimipramine.	Depression [6A70-6A7Z]	[85]
Nortriptyline	DM4KDYJ	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Nortriptyline.	Depression [6A70-6A7Z]	[85]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Flutamide and Escitalopram.	Depression [6A70-6A7Z]	[86]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Clomipramine.	Depression [6A70-6A7Z]	[85]
Trazodone	DMK1GBJ	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Trazodone.	Depression [6A70-6A7Z]	[85]
Amoxapine	DMKITQE	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Amoxapine.	Depression [6A70-6A7Z]	[85]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Doxepin.	Depression [6A70-6A7Z]	[85]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Maprotiline.	Depression [6A70-6A7Z]	[85]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[85]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Deutetrabenazine.	Dystonic disorder [8A02]	[85]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Ingrezza.	Dystonic disorder [8A02]	[85]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Flutamide and Cannabidiol.	Epileptic encephalopathy [8A62]	[85]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Solifenacin.	Functional bladder disorder [GC50]	[85]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Pentamidine.	Fungal infection [1F29-1F2F]	[85]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Ketoconazole.	Fungal infection [1F29-1F2F]	[85]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Flutamide and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[86]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[85]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Flutamide and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[96]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[85]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Flutamide and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[97]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Flutamide and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[98]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[85]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Flutamide and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[99]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Flutamide and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[86]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Flutamide and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[100]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Flutamide caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[101]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Flutamide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[85]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Flutamide and Phenolphthalein.	Irritable bowel syndrome [DD91]	[86]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Flutamide and Methotrexate.	Leukaemia [2A60-2B33]	[85]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Flutamide and Porfimer Sodium.	Lung cancer [2C25]	[102]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Flutamide and Osimertinib.	Lung cancer [2C25]	[103]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Flutamide caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[104]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Flutamide and Selpercatinib.	Lung cancer [2C25]	[85]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Flutamide and Lumefantrine.	Malaria [1F40-1F45]	[83]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Flutamide and Halofantrine.	Malaria [1F40-1F45]	[105]
Chloroquine	DMSI5CB	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Chloroquine.	Malaria [1F40-1F45]	[85]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Primaquine.	Malaria [1F40-1F45]	[85]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[85]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Flutamide and Idelalisib.	Mature B-cell leukaemia [2A82]	[106]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Flutamide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[107]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Flutamide and Clofarabine.	Mature B-cell lymphoma [2A85]	[108]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Flutamide and Vemurafenib.	Melanoma [2C30]	[86]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and LGX818.	Melanoma [2C30]	[85]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Flutamide caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[109]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Flutamide and Thalidomide.	Multiple myeloma [2A83]	[83]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Flutamide and Siponimod.	Multiple sclerosis [8A40]	[83]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Flutamide and Fingolimod.	Multiple sclerosis [8A40]	[86]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Flutamide and Ozanimod.	Multiple sclerosis [8A40]	[110]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Romidepsin.	Mycosis fungoides [2B01]	[85]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[85]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Flutamide and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[111]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Promethazine.	Nausea/vomiting [MD90]	[85]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Granisetron.	Nausea/vomiting [MD90]	[85]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Flutamide and Dolasetron.	Nausea/vomiting [MD90]	[86]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Ondansetron.	Nausea/vomiting [MD90]	[85]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Entrectinib.	Non-small cell lung cancer [2C25]	[85]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Flutamide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[85]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Lofexidine.	Opioid use disorder [6C43]	[85]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Flutamide caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[83]
Dextropropoxyphene	DM23HCX	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Dextropropoxyphene.	Pain [MG30-MG3Z]	[85]
Prilocaine	DMI7DZ2	Major	Increased risk of methemoglobinemia by the combination of Flutamide and Prilocaine.	Pain [MG30-MG3Z]	[112]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Buprenorphine.	Pain [MG30-MG3Z]	[85]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Triclabendazole.	Parasitic worm infestation [1F90]	[85]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Pimavanserin.	Parkinsonism [8A00]	[85]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Apomorphine.	Parkinsonism [8A00]	[85]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Flutamide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[113]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Famotidine.	Peptic ulcer [DA61]	[83]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Flutamide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[114]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Flutamide and Lefamulin.	Pneumonia [CA40]	[115]
Ritodrine	DM4V6RL	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Ritodrine.	Preterm labour/delivery [JB00]	[89]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[85]
Fluphenazine	DMIT8LX	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Fluphenazine.	Psychotic disorder [6A20-6A25]	[85]
Triflupromazine	DMKFQJP	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Triflupromazine.	Psychotic disorder [6A20-6A25]	[85]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Flutamide and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[116]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Flutamide and Leflunomide.	Rheumatoid arthritis [FA20]	[86]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Quetiapine.	Schizophrenia [6A20]	[85]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Flutamide and Mesoridazine.	Schizophrenia [6A20]	[86]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Flutamide and Thioridazine.	Schizophrenia [6A20]	[86]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Aripiprazole.	Schizophrenia [6A20]	[83]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Flutamide and Iloperidone.	Schizophrenia [6A20]	[86]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Paliperidone.	Schizophrenia [6A20]	[85]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Flutamide and Haloperidol.	Schizophrenia [6A20]	[86]
Perphenazine	DMA4MRX	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Perphenazine.	Schizophrenia [6A20]	[85]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Trifluoperazine.	Schizophrenia [6A20]	[85]
Risperidone	DMN6DXL	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Risperidone.	Schizophrenia [6A20]	[85]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Flutamide and Amisulpride.	Schizophrenia [6A20]	[117]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Asenapine.	Schizophrenia [6A20]	[85]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Flutamide and Pimozide.	Schizophrenia [6A20]	[85]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Vardenafil.	Sexual dysfunction [HA00-HA01]	[85]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Flutamide and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[85]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Flutamide and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[86]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[85]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Pitolisant.	Somnolence [MG42]	[85]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[85]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Flutamide and Naltrexone.	Substance abuse [6C40]	[118]
Warfarin	DMJYCVW	Moderate	Increased risk of bleeding by the combination of Flutamide and Warfarin.	Supraventricular tachyarrhythmia [BC81]	[94]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Flutamide and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[86]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Lenvatinib.	Thyroid cancer [2D10]	[85]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Flutamide and Cabozantinib.	Thyroid cancer [2D10]	[85]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Flutamide and Papaverine.	Tonus and reflex abnormality [MB47]	[119]
Tizanidine	DMR2IQ4	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Tizanidine.	Tonus and reflex abnormality [MB47]	[85]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Tacrolimus.	Transplant rejection [NE84]	[85]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[85]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[85]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Flutamide and Procainamide.	Ventricular tachyarrhythmia [BC71]	[86]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Propafenone.	Ventricular tachyarrhythmia [BC71]	[85]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Flutamide and Flecainide.	Ventricular tachyarrhythmia [BC71]	[85]
-----------


⏷ Show the Full List of 165 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 16 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Flutamide 125 mg capsule	125 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6943).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075298.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
9	The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol Lett. 2003 Apr 30;142(1-2):61-70.
10	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
11	Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
12	Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997 Nov;25(11):1298-303.
13	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
23	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
24	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
25	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
26	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
27	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
28	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
29	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
30	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
31	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
32	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
33	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
34	Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
35	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
36	A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
37	Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
38	Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
39	Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
40	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
41	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
42	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
43	Drug Interactions Flockhart Table
44	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
45	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
46	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
47	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
48	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
49	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
50	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
51	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
52	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
53	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
54	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
55	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
56	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
57	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
58	Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
59	Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
60	Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
61	Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
62	Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
63	The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
64	Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
65	Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
66	Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
67	Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
68	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
69	ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
70	Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
71	Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
72	Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
73	Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
74	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
75	Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
76	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
77	Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
78	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
79	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
80	CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
81	Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
82	An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
83	Cerner Multum, Inc. "Australian Product Information.".
84	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
85	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
86	Canadian Pharmacists Association.
87	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
88	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
89	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
90	Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
91	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
92	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
93	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
94	Product Information. Eulexin (flutamide). Schering Laboratories, Kenilworth, NJ.
95	Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
96	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
97	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
98	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
99	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
100	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
101	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
102	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
103	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
104	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
105	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
106	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
107	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
108	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
109	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
110	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
111	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
112	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
113	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
114	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
115	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
116	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
117	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
118	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
119	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]